
    
      This study will evaluate the safety, tolerability, and immunogenicity to vCP2438 (an HIV
      clade C vaccine) and to an unadjuvanted or MF59- or alum-adjuvanted bivalent clade C gp120 in
      healthy, HIV-uninfected adults.

      The study will enroll healthy, HIV-uninfected participants aged 18 to 40 years. Participants
      will be randomly assigned to one of 4 groups. [describe further]

      Study visits will include a physical examination, an interview and/or questionnaire, HIV
      testing and HIV risk-reduction counseling, and urine and blood collection. A subset of
      participants will provide rectal fluid, cervical fluid, semen, or stool samples.
    
  